Phase 1 trial of vodobatinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI): Activity in CML chronic phase patients failing TKI therapies including ponatinib Meeting Abstract
| Authors: | Cortes, J. E.; Saikia, T.; Kim, D. W.; Alvarado, Y.; Nicolini, F. E.; Khattry, N.; Rathnam, K.; Apperley, J.; Deininger, M. W.; de Lavallade, H.; Charbonnier, A.; Granacher, N.; Gambacorti-Passerini, C.; Lucchesi, A.; Mauro, M. J.; Verhoef, G.; Vandenberghe, P.; Whiteley, A. R.; Apte, S.; Yao, S. L.; Kothekar, M.; Sreenivasan, J.; Bimba, H. V.; Chimote, G. |
| Abstract Title: | Phase 1 trial of vodobatinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI): Activity in CML chronic phase patients failing TKI therapies including ponatinib |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607547200147 |
| DOI: | 10.1182/blood-2020-139847 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 51 -- Source: Wos |
